Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

205.69 -0.10 (-0.05%)
Streaming Delayed Price Updated: 1:31 PM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Charles River Laboratories Intl

< Previous 1 2 3 4 5 6 7 8 Next >
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Third-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Charles River Laboratories International, Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Charles River Laboratories to Host Virtual Investor Day
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Charles River Laboratories Announces Second-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.